NEW YORK CITY, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and global competitive advantage.

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has received a consensus rating of “Reduce” from the twelve analysts ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12.00 in a report issued on Tuesday,Benzinga reports. The firm presently has ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings ... we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI.

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50 ...

These savings were partially offset by an increase in professional fees and stock-based compensation as well as targeted hiring where necessary to support specific needs. SG&A in the quarter was ...

FORTREA ($FTRE) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of $0.18 per share, missing estimates of $0.37 by $0.19. The ...

Short interest in Fortrea Holdings Inc (NASDAQ:FTRE) decreased during the last reporting ... to close out their positions without sending the stock sharply higher.

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions.